Jump to content

User:Mr. Ibrahem/Alpelisib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Alpelisib
Clinical data
Trade namesPiqray
Other namesBYL719
AHFS/Drugs.comMonograph
MedlinePlusa619036
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classChemotherapy (PI3K inhibitor)[2]
Legal status
Legal status
Identifiers
  • (2S)-1-N-[4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
Chemical and physical data
FormulaC19H22F3N5O2S
Molar mass441.47 g·mol−1
3D model (JSmol)
  • CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
  • InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
  • Key:STUWGJZDJHPWGZ-LBPRGKRZSA-N

Alpelisib, sold under the brand name Piqray, is a chemotherapy medication used to treat certain types of breast cancer.[2] It is used together with fulvestrant.[2] It results in about an extra 5 months of life without the disease getting worse.[4] It is taken by mouth.[2]

Common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss.[5] Other side effects may include anaphylaxis, infertility, and pneumonitis.[2] Use during pregnancy may harm the baby.[2] It is an alpha-specific PI3K inhibitor.[2]

Alpelisib was approved for medical use in the United States in 2019 and Europe in 2020.[2][4] In the United States a month of medication costs about 17,000 USD as of 2021.[7]

References[edit]

  1. ^ a b "Piqray Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 27 March 2020. Archived from the original on 27 August 2021. Retrieved 16 August 2020.
  2. ^ a b c d e f g h i "Alpelisib Monograph for Professionals". Drugs.com. Archived from the original on 4 November 2019. Retrieved 19 July 2021.
  3. ^ "Piqray- alpelisib tablet Piqray- alpelisib kit". DailyMed. 12 June 2020. Archived from the original on 28 October 2020. Retrieved 16 August 2020.
  4. ^ a b c "Piqray EPAR". European Medicines Agency (EMA). 26 May 2020. Archived from the original on 14 August 2020. Retrieved 16 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ a b "FDA approves first PI3K inhibitor for breast cancer". U.S. Food and Drug Administration (FDA) (Press release). 24 May 2019. Archived from the original on 25 November 2019. Retrieved 29 May 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ "Alpelisib (Piqray) Use During Pregnancy". Drugs.com. 29 July 2019. Archived from the original on 3 December 2020. Retrieved 16 August 2020.
  7. ^ "Piqray Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 6 October 2021. Retrieved 19 July 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Alpelisib&oldid=1213866554"